AQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier
AQEMIA Boosts Series A Funding to €60M
PARIS--(BUSINESS WIRE)--AQEMIA, a pioneering pharmatech company leveraging AI and quantum-inspired physics to accelerate the discovery of small molecule drug candidates with higher probability of success in the clinic, announces a multi-year research collaboration with the global pharmaceutical company Sanofi. The collaboration aims at discovering small molecule drug candidates across several therapeutic areas. AQEMIA will leverage its unique platform that combines deep physics with generative AI at scale to identify the right chemical molecules for therapeutic targets of interest to Sanofi.
Another day, another artificial intelligence (AI) deal. Tuesday was Sanofi’s turn to partner up, striking a deal worth up to $140 million to work on the discovery of small molecules with its compatriot Aqemia.
Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology